Risk factors for mortality in Type II (non-insulin-dependent) diabetes: Evidence of a role for neuropathy and a protective effect of HLA-DR4

Diabetologia

Volumn 41, Issue 11, 1998, Pages 1253-1262

  Forsblom, C M ^a   Sane, T ^a   Groop, P H ^a   Totterman K J ^a   Kallio, M ^b   Saloranta, C ^a   Laasonen, L ^a   Summanen, P ^a   Lepantalo M ^b   Laatikainen, L ^a   Matikainen, E ^c   Teppo, A M ^a   Koskimies, S ^d   Groop, L ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Surgical Hospital   (Finland)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d FINNISH RED CROSS BLOOD SERVICE   (Finland)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Cardiovascular risk factors; HLA DR4; Immunological markers; Microalbuminuria; Mortality; NEFA; Neuropathy; Type II (non insulin dependent) diabetes mellitus

Indexed keywords

ALBUMIN; FATTY ACID; HEMOGLOBIN A1C; HLA DR4 ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ALBUMINURIA; AUTOIMMUNITY; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; FATTY ACIDS, NONESTERIFIED; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HLA-DR ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; MALE; MIDDLE AGED; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 15444360456     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051062     Document Type: Article

References (49)

1. Hanssen KF, Dahl-Jörgensen K, Lauritzen T, Feldt-Rasmussen B, Brinchmann-Hansen O, Deckert T (1986) Diabetic control and microvascular complications: the near-normoglycaemic experience. Diabetologia 29: 677-684
2. Abraira C, Colwell J, Nuttall F et al. (1997) Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157: 181-188
3. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M (1994) NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960-967
4. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H (1995) Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44: 1303-1309
5. West KM, Ahuja MMS, Bennett PH et al. (1983) The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO Multinational Study. Diabetes Care 6: 361-369
6. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K (1990) 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82: 27-36
7. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607
8. Groop L, Tuomi T (1997) Non-insulin dependent diabetes mellitus - A collision between thrifty genes and an affluent society. Ann Med 29: 37-53
9. Tuomi T, Groop LC, Zimmet PL, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42: 359-362
10. Turner R, Stratton I, Horton V et al. (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288-1293
11. Lehto M, Tuomi T, Mahtani M et al. (1997) Characterization of the MODY3 phenotype: early-onset diabetes caused by an insulin secretion defect. J Clin Invest 99: 582-591
12. Isomaa B, Henricsson M, Lehto M et al. (1998) Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 41: 467-473
13. Groop L, Miettinen A, Groop P-H, Meri S, Koskimies S, Bottazzo GF (1988) Organ-specific autoimmunity and HLA-DR antigens as markers for β-cell destruction in patients with type II diabetes. Diabetes 37: 99-103
14. Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh C-D, Lernmark Å (1996) HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM. Diabetologia 39: 1313-1317
15. World Health Organization Study Group on Diabetes Mellitus (1985) Technical report series No 727, WHO, Geneva
16. Faber OK, Binder C (1977) C-peptide response to glucagon. A test for the residual β-cell function in diabetes mellitus. Diabetes 26: 605-610
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
18. Rose GA, Blackburn H (1968) Cardiovascular survey methods. World Health Organization, Geneva, pp 137-154
19. Darling RC, Raines JK, Brener BJ, Austen WG (1972) Quantitative segmental pulse volume recorder: a clinical tool. Surgery 72: 873-887
20. Lepäntalo M, Lindfors O, Pekkola P (1983) The ankle/arm systolic blood pressure ratio as a screening test for arterial insufficiency in the lower limb. Ann Chirurg Gynaecol 72: 57-62
21. Nielsen PE, Bell G, Lassen NA (1972) The measurement of digital systolic blood pressure by strain gauge technique. Scand J Lab Invest 29: 371-379
22. Heding LG (1972) Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260-266
23. Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541-548
24. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353
25. Sane T, Nikkilä EA (1988) Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal. Arteriosclerosis 8: 217-226
26. Miles J, Glasscock R, Aikens J, Gerich J, Haymond M (1983) A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24: 96-99
27. Rowley MJ, Mackay IR, Chen Q-Y, Knowles W, Zimmet PZ (1992) Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 41: 548-551
28. Tuomilehto-Wolf E, Tuomilehto J, Hitman GA et al. (1993) Genetic susceptibility to non-insulin dependent diabetes mellitus and glucose intolerance are located in HLA region. BMJ 307: 155-159
29. Charron D (1990) Molecular basis of human leukocyte antigen class II disease associations. Adv Immunol 48: 107-159
30. Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82: 495-506
31. Lahdenperä S, Syvänne M, Kahri J, Taskinen M-R (1996) Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary heart disease: importance of serum triglycerides. Diabetologia 39: 453-461
32. Arner P (1995) Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 27: 435-438
33. Pan DA, Lillioja S, Kriketos AD et al. (1997) Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46: 983-988
34. Eriksson K-F, Laurila E, Kiens B, Groop L (1997) Skeletal muscle triglycerides in impaired glucose tolerance and NIDDM. Diabetologia 40 [Suppl 1]:A286 (Abstract)
35. Reynisdottir S, Ellerfeldt K, Wahrenberg H, Lithell H, Arner P (1994) Multiple lipolysis defects in the insulin resistance (metabolic) syndrome. J Clin Invest 93: 2590-2599
36. Groop LC, Bonadonna RC, Shank M, Petrides AS, De-Fronzo RA (1991) Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man. J Clin Invest 87: 83-89
37. Saloranta C, Groop L (1996) Interactions between glucose and FFA metabolism in man. Diabetes/Metabol Rev 12: 15-36
38. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G (1992) Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41: 736-741
39. Damsgaard EM, Fröland A, Jörgensen OD, Mogensen C-E (1992) Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 41: 731-735
40. Neil A, Hawkins M, Potok M, Thorogood M, Cohen D, Mann J (1993) A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 16: 996-1003
41. MacLeod JM, Lutale J, Marshall SM (1995) Albumin excretion and vascular deaths in NIDDM. Diabetologia 38: 610-616
42. Niskanen L, Penttilä I, Parviainen M, Uusitupa MIJ (1996) Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care 19: 486-493
43. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360
44. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A (1989) Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32: 219-226
45. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH (1992) Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet 340: 319-323
46. Groop L, Ekstrand A, Forsblom C et al. (1993) Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 642-647
47. Forsblom CM, Eriksson JG, Ekstrand AV, Teppo A-M, Taskinen M-R, Groop LC (1995) Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM. Diabetologia 38: 363-369
48. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K (1993) Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36: 1175-1184
49. Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MIJ (1996) Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 45: 308-315